Dr. Misako Nagasaka, MD
Claim this profileUniversity of California - Irvine Medical Center
Studies Non-Small Cell Lung Cancer
Studies Tumors
16 reported clinical trials
20 drugs studied
Area of expertise
1Non-Small Cell Lung Cancer
Stage IV
EGFR positive
Stage III
2Tumors
Stage IV
Stage III
ALK positive
Affiliated Hospitals
Clinical Trials Misako Nagasaka, MD is currently running
JIN-A02
for Non-Small Cell Lung Cancer
This study is a Phase I/II open-label, multi-center study to evaluate the safety, tolerability, PK, and an anti-tumor activity of JIN-A02, a 4th generation EGFR-TKI agent for oral administration, in EGFR mutant-positive, advanced NSCLC subjects who showed disease progression after receiving standard anticancer therapy, including approved EGFR-TKI therapy and/or no more than a single platinum-based anticancer chemotherapy. In Part A of the study, dose escalation is carried out where MTD is evaluated using Bayesian Optimal Interval (BOIN) design in subjects with advanced NSCLC harboring EGFR-mutation of C797S or T790M. In Part B, dose exploration is carried out to further evaluate the safety of JIN-A02 and to determine the RP2D using 2 preliminary effective dose levels and with the help of a safety review committee (SRC) in advanced NSCLC subjects harboring EGFR mutant C797S or T790M. In Part C dose expansion study, subjects with EGFR mutant who show disease progression after receiving standard anticancer therapy, including approved EGFR-TKI therapy with activity against T790M such as Osimertinib and/or no more than one platinum-based anticancer chemotherapy, are divided into 5 different cohorts based on the EGFR mutation and the anti-tumor activity of JIN-A02 is evaluated. Before enrollment in the study, the EGFR mutant profile is determined using either tumor tissue and/or plasma ctDNA. The profile is determined locally through a test method approved by the sponsor. The sponsor reviews and approves each potential subject for enrollment. Study eligibility evaluation will utilize local test(s).
Recruiting1 award Phase 1 & 212 criteria
CAB-ROR2-ADC + PD-1 Inhibitor
for Breast Cancer
This trial is testing a new targeted cancer treatment called CAB-ROR2-ADC in patients with advanced solid tumors. The drug seeks out cancer cells with a specific marker and delivers a potent treatment directly to them.
Recruiting1 award Phase 1 & 29 criteria
More about Misako Nagasaka, MD
Clinical Trial Related1 year of experience running clinical trials · Led 16 trials as a Principal Investigator · 9 Active Clinical TrialsTreatments Misako Nagasaka, MD has experience with
- Seribantumab
- TPX-0022
- Osimertinib
- EMB-01
- LGK974
- PDR001
Breakdown of trials Misako Nagasaka, MD has run
Non-Small Cell Lung Cancer
Tumors
Solid Tumors
Head and Neck Cancers
Other Doctors you might be interested in
Frequently asked questions
Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Misako Nagasaka, MD specialize in?
Misako Nagasaka, MD focuses on Non-Small Cell Lung Cancer and Tumors. In particular, much of their work with Non-Small Cell Lung Cancer has involved Stage IV patients, or patients who are EGFR positive.
Is Misako Nagasaka, MD currently recruiting for clinical trials?
Yes, Misako Nagasaka, MD is currently recruiting for 9 clinical trials in Orange California. If you're interested in participating, you should apply.
Are there any treatments that Misako Nagasaka, MD has studied deeply?
Yes, Misako Nagasaka, MD has studied treatments such as Seribantumab, TPX-0022, Osimertinib.
What is the best way to schedule an appointment with Misako Nagasaka, MD?
Apply for one of the trials that Misako Nagasaka, MD is conducting.
What is the office address of Misako Nagasaka, MD?
The office of Misako Nagasaka, MD is located at: University of California - Irvine Medical Center, Orange, California 92868 United States. This is the address for their practice at the University of California - Irvine Medical Center.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.